|If you are in a crisis,|
please call: 1-800-SUICIDE (784-2433)
| IBPF WELCOMES NEW BOARD MEMBER|Joye Blount
Joye has more than 17 years of experience in banking including philanthropic management, strategic communications, personnel management, private wealth management, trust and investments. She holds a FINRA Series 7, 66 certifications in addition to a Six Sigma Green Belt certification. She has earned numerous national business and community awards and nominations including YWCA Twin Award, Women Who Mean Business Award and Women Who Move the City Award. She has served as a United Nations Official Observer for the Mexican presidential election in 2001 and 2006. She is also a graduate of the FBI Citizen's Academy and earned a B.S. Degree in Education from Winthrop University and a Master's Degree in Leadership from The University of North Carolina.
Active in the San Diego community, Joye serves on the boards of The Point Loma Nazarene University President's Advisory Board, Point Loma Nazarene University School of Business Advisory Board, The Salk Institute Community Advisory Board, Voices for Children Advisory Board, and The United Way Women's Leadership Council, and most recently was appointed by the Mayor to serve on the Balboa Park Conservancy Task Force. She is also an active volunteer with The San Diego Symphony, The San Diego Futures Foundation, The San Diego Symphony and The Zoological Society of San Diego.
Joye resides in San Diego with her husband, Jessie J. Knight, Jr.
IBPF FREE LECTURE SERIES
Our Lecture Series are now available for viewing on our web site!! Click here
- The 5 Most Common Mental Issues Teens Face - Dr. Thomas Jensen
- Going to College with Bipolar Disorder - Dr. Russ Federman
- Runaway Mind - Maggie Reese
- A Novel Approach to Treating Bipolar Disorder - Depression Bipolar Institute
- Irwin Rosenfarb: Family Treatment for Bipolar Disorder
Our Next Lecture:
Rev. Dr. Beth A. Cooper is a United Methodist elder. For over twenty years she has served local churches and campus ministries. She is a graduate of Duquesne University with a Master of Sacred Music and Master of Divinity degree from Perkins School of Theology at Southern Methodist University. She received her Doctorate degree in Ministry from Wesley Theological Seminary. She also received a graduate certificate in Women Studies from San Diego State University. Rev. Dr. Beth A. Cooper is currently the Executive Director at The Wesley Foundation.
November 10, 2011- Rev. Beth Cooper: GAINING GROUND: CONNECTIONS BETWEEN SPIRITUALITY AND MENTAL HEALTH (focus on Young Adults)
5:30-6:00- SOCIAL 6:00-6:45-LECTURE 6:45-7:00- Q & A
Location: Sanford Children's Research Center, Building 12 Address: 10905 Road to Cure, San Diego 92121
Save the date for these lectures in La Jolla:
December 8th, 2011- David Miklowitz Ph.D.: Bipolar Disorder: Eight Strategies for Coping as an Individual and a Family
Good Perfectionism versus Bad Perfectionism
By THERESE J. BORCHARD
Although perfectionism undoubtedly brings me suffering and pain, I've come to appreciate the snobby part of my personality because it also bear gifts, especially over time. Read the rest of the blog here
|2012 Bipolar Lives Scholarship Now Open|
The 2012 Bipolar Lives Scholarship is now open for entries.
This is a MERIT based scholarship and will be awarded, as in previous years, to the person or persons who most eloquently communicates important information about bipolar disorder.
The 2012 Bipolar Lives Scholarship is a cash award of $1,000.00 USD, with the winner announced on July 1st, 2012.
Entries will close at midnight EST on Friday June 15th, 2012.
What do we mean by MERIT based? It means the Bipolar Lives Scholarship is awarded on the basis of academic excellence.
It is NOT awarded based on need.
The winning entry or entries will be an excellent academic essay about an important or overlooked aspect of bipolar disorder.
It should be original work and demonstrate research skills, writing skills, and insight into bipolar disorder. This means a personal perspective is welcome, but please understand the judging panel are not looking for hard luck stories, sob stories, or purely personal anecdotes.
The best way to understand what the judging panel looks for is to read winning entries from previous years: here
Have a little faith
By Robin L. Flanigan
Marja B. found God at her public library.
Born into a Christian family, she went to Sunday School because it was expected. As a teenager, she turned her back on religion. By the time she turned 40, with a recent diagnosis of bipolar disorder after two decades of uncontrolled symptoms, she was ready for a spiritual quest. So she went to the library. here
IBPF's lecture on November 10 is Gaining Ground: Connections between Sprituality & Mental Health with Rev. Beth Cooper
Teens may provide clues to link between bipolar and heart disease
Sunnybrook Health Sciences Centre--For the first time, researchers will be comparing blood vessel functioning of teens with bipolar disorder and healthy teens, to look for potential clues about heart disease risk. read more
Gene Regulatory Protein Is Reduced in Bipolar Disorder
Low levels of a brain protein that regulates gene expression may play a role in the origin of bipolar disorder, a complex and sometimes disabling psychiatric disease. As reported in the latest issue of Bipolar Disorders, the journal of The International Society for Bipolar Disorders, levels of SP4 (specificity protein 4) were lower in two specific regions of the brain in postmortem samples from patients with bipolar disorder. The study suggests that normalization of SP4 levels could be a relevant pharmacological strategy for the treatment of mood disorders. read more
Steve Jobs: Limits of Magical Thinking
First Generic Olanzapine For Schizophrenia And Bipolar Disorder Treatment
Approved By FDA
Generic versions of olanzapine tablets (Zyprexa) and olanzapine orally
disintegrating tablets (Zyprexa Zydus) for the treatment of schizophrenia and
bipolar disorder have been approved by the US Food and Drug Administration
Studying The Genetic Causes Of Bipolar Disorder Could Lead To New Treatments
Researchers at the University of Leeds investigating the genetic causes of
bipolar disorder have identified two new drugs = one of which has already been
found safe in clinical trials - that may be effective in treating the disorder. here
Gene Regulatory Protein Is Reduced In Bipolar Disorder
Low levels of a brain protein that regulates gene expression may play a role in
the origin of bipolar disorder, a complex and sometimes disabling psychiatric
disease. As reported in the latest issue of Bipolar Disorders, the journal of
The International Society for Bipolar Disorders, levels of SP4 (specificity
protein 4) were lower in two specific regions of the brain in postmortem samples
from patients with bipolar disorder. here
Validity of the Chinese version Mood Disorder Questionnaire (MDQ) and the optimal cutoff screening bipolar disorders
This study demonstrated the good validity of Chinese version of Mood Disorder Questionnaire (C-MDQ) in China. The best cutoff between BP-II and UP can be regarded as the optimal cutoff between BP and UP to improve the sensitivity of screening for BP-II. Five should be the optimal cutoff between the BP and UP when only the 13 items of the questionnaire are used in China. here
Glucocorticoid and mineralocorticoid receptor polymorphisms and clinical characteristics in bipolar disorder patients
Polymorphisms of the GR-gene are factors which influence some clinical manifestations of BD, with respect to seasonal pattern of (hypo)mania and age of onset. here
L.A. County expands no-cost healthcare
Hoping to establish new programs before Medi-Cal takes over in 2014, it plans to register as many as 550,000 patients and assign them to medical clinics for free services.
In one of the largest expansions of health coverage to the uninsured, Los Angeles County is enrolling hundreds of thousands of residents in a publicly funded treatment program and setting the stage for the national healthcare overhaul. read more
More Children Visiting ERs for Psychiatric Care
A growing number of American children are receiving psychiatric care in hospital emergency departments, particularly children who have no insurance or are covered by Medicaid.
That's the finding of a new study that examined 279 million visits made by children to U.S. emergency departments from 1999 to 2007. here
Study says Postural Problems may be a sign of Bipolar Disorder
New clinical research study to compare two medications for bipolar disorder
Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications -- quetiapine (Seroquel), a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer. here
|Husseini Manji, |
Co-Chair of International Bipolar Foundation's Scientific Advisory Board
J&J neuroscience head urges pooling of brain R&D
By Sten Stovall
LONDON (MarketWatch) -- A top scientist from Johnson & Johnson (NYSE:JNJ) is in Europe this week to urge pharmaceutical companies, academia and governments there to join a U.S. initiative to combine research efforts to better understand and battle brain disease, one of the most devastating illnesses facing mankind.
Husseini Manji, J&J's global therapeutic area head for neuroscience, has arranged meetings in London and Brussels to promote a new initiative called "One Mind for Research".
"Neuropsychiatric diseases are the most burdensome to society and among the most complex illnesses," Manji said in an interview with Dow Jones Newswires. "So business as usual in this disease area isn't going to work."
Declining government and corporate funding for research into disorders of the brain poses a serious threat to the development of new medicines for conditions such as schizophrenia, stroke, bipolar disorder, depression, anxiety and autism.
Brain disorders represent 35% of the total disease burden in Europe, according to a report published in the European Neurological Review.
But costly failures in late-stage drug trials have persuaded some companies including the U.K.'s GlaxoSmithKline PLC (NYSE:GSK) and AstraZeneca PLC (NYSE:AZN) to close down their research activities into a range of brain diseases such as depression, given the scientific uncertainties in the field and the problems in finding new advances.
"In the past everyone did their own thing. What's clear now is that if you're choosing to stay in this disease area, whether you're an academic researcher or a government researcher or industry researcher, you're going to go far, far further by trying to work together than in isolation," Manji said.
Launched in May and backed by former U.S. Congressman Patrick Kennedy, "One Mind for Research" aims to build a global network and data repository of all relevant imaging, genome, and patient records. The initiative wants to pool early stage assets and neuroscience insight to find cures for brain disorders.
"The plan has always been to kick it off in the U.S. and very quickly try and make it at least a trans-Atlantic endeavor, if not a global endeavor," Manji said.
Manji has been holding talks with counterparts at other large pharmaceutical companies about joint funding efforts with other organizations including the US National Institutes of Health and the EU-led Innovative Medicines Initiative, which funds cross-border corporate and academic work.
The key part of the plan is to have open access at the early stages of R&D.
"Some of it would be completely open so that the data generated is available to everyone to benefit from. This would pertain to what we call pre-competitive research. After that, the race would be on for companies to develop their own products."
"There's no question that different companies are sometimes duplicating effort by perhaps looking at and coming up with the same animal model and the same targets. Collaboration could allow us to come up with a better animal model or a better biomarker to predict who's at risk of Alzheimer's Disease and so on," said Manji, who worked at the National Institutes of Health before joining J&J.
"Our knowledge base and data are largely siloed, and incentives for research and collaboration are lacking. We're going to learn a lot more about these diseases by breaking down the silos than we would have working in isolation."
Dear Friend & Advocate|
Are children with ADD/ADHD eligible for special education services under the IDEA?
Are children with ADD/ADHD eligible for accommodations and modifications under Section 504?
Can these children be suspended or expelled?
Answers: maybe, maybe, and maybe.
In this issue of the Special Ed Advocate, you will find answers to your questions about getting services for a child with ADHD and how to present your child's problems to school staff so they want to help.
Bipolar Disorder Risk Factors Found in Families
Children who grow up in families where other mental disorders are present - such as attention deficit hyperactivity disorder (ADHD) or anxiety - appear to be at greater risk for developing bipolar disorder later in life, according to new research. here
Generic Zyprexa OK'd by FDA for Schizophrenia, Bipolar Disorder
The U.S. Food and Drug Administration (FDA) on Monday approved the first generic versions of Zyprexa (olanzapine tablets) and Zyprexa Zydus (olanzapine orally disintegrating tablets) to treat schizophrenia and bipolar disorder. here
NEWS FROM NAMI, DBSA, & SAMHSA
NAMI San Diego
Ask the Doctors and a Presentation by Recovery International Self-Help Resources
Free Education and Advocacy Meeting
Thursday, November 3, 2011, 6:30 p.m.
For more information, contact NAMI San Diego at (800) 523-5933. Or visit www.namisandiego.org
DBSA San Diego:
Lecture by Dr. David Gersten entitled "Nutritional Healing: Focus on Amino Acid Therapy." Monday November 7th at 6pm
This lecture is free and open to the public.
DBSA members and their family and friends are invited to our annual Thanksgiving feast at Hometown Buffet on Clairemont Dr.
If you cannot afford the $5 but would still like to come, please speak with a group leader. More information here
Help Support National Drug Facts Week
October 31-November 6, 2011
SAMHSA invites you to participate in the second annual National Drug Facts Week (NDFW) sponsored by the National Institute on Drug Abuse (NIDA). NDFW is a health observance week to help teens shatter the myths about drugs and drug abuse and get factual answers through community-based events and activities.
SAVE THE DATE
A Free Workshop for Fusion Families and Members of the Community
Join us for this free informational workshop to gain a better understanding of the IEP/ISP/504 process.
Wednesday, November 2, 6:00 p.m. RSVP: email@example.com or call 858-792-2300
FREE IEP Evaluation Day I am offering a free "IEP Evaluation Day" on Saturday November 5, 2011, between 11am and 5pm, where parents can bring their IEPs and have their IEP questions answered. 16466 Bernardo Center Dr., Ste. 106, San Diego, CA 92128. Click this flyer for more information
Save the date for our free monthly lectures in La Jolla:
November 10th, 2011- Beth Cooper: Spirituality and Mental Health
December 8th, 2011- David Miklowitz: Bipolar Disorder: Eight Strategies for Coping as an Individual and a Family
2011 U.S. Psychiatric and Mental Health Congress:
November 8-9, 2011
Conference dates: November 7-10
The Venetian Hotel & Congress Center
Carlsbad Marathon: January 22: IBPF is one of the designated charities for the 2012 marathon.
Sign up here
About the International Bipolar Foundation
International Bipolar Foundation is a not for profit organization based in San Diego whose mission is to eliminate Bipolar Disorder through the advancement of research; to promote care and support services; and to erase associated stigma through public education.
Visit us online for more information: www.internationalbipolarfoundation.org
We have a new Community Page on FaceBook.
Please join us on Facebook and "Like" us and help us spread the word.
A Word About Funding
Please note that International Bipolar Foundation does not represent any pharmaceutical company or give any speeches for a pharmaceutical company nor does our site receive advertising dollars from any company.